Corporate
2023.07.26
LT3001 Received Formulation Patent from USPTO
Corporate
2023.05.15
Lumosa’s LT1001 Received First European Approval from Ukraine’s SMDC
Corporate
2023.04.19
First subject for LT3001 Phase 2 trial enrolled in China
Corporate
2023.03.07
Lumosa Therapeutics Announces an Out-License Agreement with Pakistan’s AJM Pharma for LT1001
Corporate
2023.02.10
Lumosa Attending the 2023 International Stroke Conference
Corporate
2022.11.01
Lumosa Exhibiting at CPhI Frankfurt 2022